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Abstract
Determination of atorvastatin in human plasma using LC-MS/MS has been widely accepted as an effective method
owing to its practical applicability in routine drug analysis in pharmacokinetic and pharmacogenetic study.  Nevertheless, the
method sensitivity can be compromised when limited sample volume is available.  This problem is typically encountered in
pharmacokinetics  studies  for  which  only  a  small  volume  of  plasma  sample  can  be  obtained.   Drug  extraction  from  human
plasma was performed with the aid of reversed-phase C18 solid phase micro-extraction. The detection was accomplished by
LC-MS/MS.  The need of plasma volume of less than 250 µl for each sample made it possible to decrease the sample prepara-
tion time.  The method was successfully validated and proved appropriate for the analysis of atorvastatin in human plasma
and can be applied to pharmacokinetics and pharmacogenetics study.
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1. Introduction
Atorvastatin is a HMG-CoA reductase inhibitor, which
has a widespread use in the prevention of cardiovascular
event.  Atorvastatin is rapidly absorbed after oral administra-
tion.  However,  due  to  pre-systematic  clearance  in  gastro-
intestinal mucosa and metabolism in the liver, its absolute
bioavailability is approximately 12 % and low plasma con-
centration is achieved following administration of the drug
(Schachter, 2005). Thus, quantification methods of the drug
in pharmacokinetic studies need to be sensitive and specific.
For atorvastatin, several HPLC methods for the determination
of drug in human plasma have been previously published.
Most extraction methods use liquid-liquid extraction (LLE)
for sample preparation and these methods have been applied
in clinical studies, with atorvastatin dose regimen 40 and 80
mg (Pilli et al., 2011; Nirogi et al., 2006; Bullen et al.,1999;
Jemal et al., 1999).  Other extraction methods such as solid
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phase  extraction  (SPE)  have  been  used  for  atorvastatin
plasma sample (Hermann et al., 2005; Vlckova et al., 2011;
Shah et al., 2011; Bahrami et al., 2005).
However,  sensitivity  can  be  compromised  when
limited sample volumes are available, which is common in
pharmacokinetics studies involving small volume of plasma
from human or animal.  To create a micro volume SPE device,
a reversed phase C18 SPE (Omix
® 100 µl C18) is packed in a
100 µl pipette tip.  The monolithic nature of the SPE sorbent
allows less restricted bi-directional flow of liquid though the
bed, unlike traditional silica bed-based materials. Thus, the
aim of this study is to develop a chromatographic method for
determination the atorvastatin in human plasma, using solid
phase micro-extraction and to apply it to pharmacokinetic
study.
2. Methods and Materials
2.1 Reagents and chemical
Atorvastatin calcium (M.W.; 604.69) and Fluvastatin
sodium (M.W.; 410.46) were purchased by Aldrich. Analy-
tical  HPLC  grade  methanol,  HPLC  grade  acetonitrile  and
formic acid were obtained from J.T. Bakers, USA. Ammonium
acetate and water were obtained from Merck, Germany.
2.2 Bioanalytical methods of atorvastatin
2.2.1  Preparation of standard solutions
Atorvastatin standard solutions were prepared from
0.1 mg/ml stock solution in 50% acetonitrile in water.  The
calibration and the quality control (QC) samples were in the
range of 0.2–80 ng/ml.  Fluvastatin was used as an internal
standard (IS) at the concentration of 12 ng/ml prepared in the
same diluent as for atorvastatin.
2.2.2 Sample preparation and solid-phase micro-extraction
extraction
The plasma samples 250 l were spiked with 50 l of
internal standard, 200 l of 0.1 mM acetic acid (pH=3) and
then vortexed and centrifuged at 31514 ×g for 10 min.  After
centrifugation,  the  total  of  100  l  of  supernatant  was  sub-
sequently  transferred  to  SPE.  A  reversed  phase  C18  SPE
sorbent material was packed in a 100 l pipette tip to create a
micro volume SPE device (OMIX
® 100 l C18).  Plasma
samples of healthy volunteers were spiked with the IS solu-
tion  before  passing  through  the  SPE  step  as  the  follows;
To prepare sorbent condition, 100 l of 100% methanol and
100 l of 0.1 mM acetic acid, pH3 were twice pipette, respec-
tively. The 100 l of prepared sample was then loaded with
slowly eluted sample out of the tip. The rinse step was done
by  loading  100  l  of  5%  aqueous  methanol  followed  by
elution. The sorbent bed were dried by quickly force the air
through the tip 2 to 4 times. Then, 100 l of 95:5 methanol:
10 mM aqueous formic acid was loaded and eluted. This step
was repeated for total elution volume of 500 l. Next, total
elution was evaporated to be dried under stream nitrogen
and the residual was reconstituted in 100 l of acetonitrile:
water (50:50 V/V) and centrifuged at 31514 ×g, 10 min at 4°C,
prior to transferal to HPLC vial and injection of 10 l in the
HPLC system.
Afterward, the reconstituted plasma sample was ana-
lyzed  by  LC-MS/MS  analysis.  The  QC  sample  was  also
treated in the same fashion as for the plasma samples.
2.2.3 LC-MS/MS conditions for the analysis of atorvastatin
Chromatographic conditions
The LC system consisted of an Algilent™ Serial 1100
LC binary pump and an auto-sampler. The analytes were
separated through Higgins C18 (3.0 mm * 100 mm, 5 µM) at a
flow rate of 0.6 ml/min, 30°C. The mobile phase composed of
solvent A (10mM ammonium acetate) and solvent B (aceto-
nitrile).  The gradient was as follow: solvent B held at 40%
for 2 min, linearly ramped from 40% to 60% in 1 min, ramp
60% to 90% in 1 min, remains 90% 3 min and bought back
down  to  40%  for  equilibration.  Total  run  time  was  10  min
with flow rate of 0.6 ml/min acetonitrile. The retention time
of atorvastatin and fluvastatin was about 4.5±0.5 min.
MS/MS conditions
Mass spectrometric detection was performed on an
API 4000 triple quadrupole instrument (ABI-SCIEX, Toronto,
Canada) using multiple reaction monitoring. A turbo electro-
spray interface in positive ionization mode was used. The
main  working  parameters  of  the  mass  spectrometer  are
summarized in Table1. Data processing was performed on
Analyst 1.4 software package (SCIEX).  The quantitation was
performed using multiple reaction monitoring (MRM) pre-
cursor-product  ion  transitions  at  m/z  559.2  to  440.1  for
Table 1. Tandem mass-spectrometer main working
parameters
                 Parameter (Unit) Value
Source temperature (°C) 400
Dwell time per transition (ms) 200
Ion source gas 1 (psi) 20
Ion source gas 2 (psi) 40
Curtain gas (psi) 25
Collision gas (psi) 5
Ion spray voltage (V) 5500
Entrance potential (V) 10
Declustering potential (V) 98 (analyte) and 80 (IS)
Collision energy (V) 50 (analyte) and 30 (IS)
Collision cell exit potential (V) 30 (analyte) and 13 (IS)
Mode of analysis Positive
Ion transition for atorvastatin (m/z) 559.2/440.1
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atorvastatin acid and m/z 412.2 to 224.2 for the IS, respec-
tively.
2.3 Pharmacokinetics study
The WinNonlin professional edition version 3.1 wes
used  for  noncompartmental  analysis.  The  plasma  concen-
tration  time  profile  for  each  subject  was  fitted  using  non-
compartmental  model  of  extravascular  input.  The  z  was
calculated  according  to  the  log-linear  portion  of  terminal
phase of plasma concentration time course. The time range
for  determining  z  was  selected  to  get  log-linearity,  then
AUClast  was  calculated.  The  Tmax  and  Cmax  were  observed
directly from the plasma concentration time curve. The means
of these parameters for atorvastatin tablets were calculated.
3. Results and Disscussion
3.1 Mass spectrometry
In order to develop a method with the desired sensi-
tivity (< 1 ng/ml), it was necessary to use MS/MS detection,
as the compound did not possess UV absorbance or fluores-
cence properties needed to achieve this limit. The inherent
selectivity  of  MS-MS  detection  was  also  expected  to  be
beneficial  in  developing  a  selective  and  sensitive  method.
The  positive  ion  TurboIonspray  Q1  mass  spectrum  and
product ion mass spectrum of atorvastatin are shown in Fig-
ure 1 and Figure 2, respectively. The [M + H]
+ was the pre-
dominant ion in the Q1 spectrum, and was used as the pre-
cursor ion to obtain product ion spectra. The most sensitive
mass transition was from m/z 559.2 to 440.1 for atorvastatin
and m/z 414.2 to 224.2 for fluvastatin (internal standard; IS)
(Figures 3 and 4). However, another mass transition from
m/z 559.2 to 250.1 for atorvastatin was detected in the same
times.
The ion spray voltage, declusturing potential, entrance
potential, collision energy and collision cell exit potential were
optimized to deliver effective fragmentation of the [M + H]
+
without excessive fragmentation, which would have reduced
sensitivity.  The parameters are presented in Table 1.
3.2 Performance of LC
The HPLC conditions were optimized such that the
retention time was kept short at about 4.5±0.5 min in order to
assure high throughput (Figure 5). The total runtime for each
sample was 10 min by using mixture of 50 mM ammonium
acetate  buffer/acetonitrile  (60:40).  The  Higgen  C18  HPLC
column (5m, 100 mm × 3 mm) was chosen based on peak
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shape and the best response for atorvastatin and fluvastatin
with acceptable analysis time.
3.3 Bioanalytical method validation
The method validation of bioanalysis was performed
as  stated  in  US-FDA  guideline.  Specificity,  selectivity,
% recovery, linearity, limit of detection, limit of quantitation,
stability, accuracy and precision were analyzed.
3.3.1  Specificity and selectivity
The specificity/selectivity of the method was investi-
gated by analyzing six blank human plasma extract (n=6) (Fig-
ure 5) and extract of spiked drug (Figure 6). No significant
interference in the blank plasma traces was seen from endo-
genous substances in drug free human plasma at the reten-
tion time of the analyte. Under the chromatographic condi-
tions described, atorvastatin and the internal standard were
eluted with nearly the same retention time.
3.3.2  Extraction recovery
The average recoveries for atorvastatin at three differ-
ent concentrations (low, medium and high QC samples) are
presented in Table 2. The recovery of the internal standard
was 84.16% at the concentration used in the assay (24 ng/ml).
3.3.3  Calibration curve
Calibration curve was linear over the concentration
range of 0.2-80 ng/ml for analyte. The calibration curve was
fitted to a 1/x
2 weighted linear regression (where x is the con-
centration of the analyte) as this was judged to be the weight-
ing  which  made  the  assay  most  robust.  The  mean  linear
regression equation of calibration curve for the analyte was
y = 0.0312(±0.0286) + 1.8250(±0.2668) x, where y was the
peak area ratio of the analyte to IS and x was the concentra-
tion of the analyte. The mean correlation coefficient of the
weighted calibration curves generated during the validation
was 0.9965 for the analyte.
Figure 2.  Full scan positive ion TurboIonspray product ion mass spectra of atorvastatin.
Table 2. The recoveries of atorvastatin
Sample concentration Recovery (%)
(ng/ml) (mean ± SD, n=6)
0.25 (QC A)    84.16±7.99
10 (QC B)    96.82±6.14
40 (QC C) 102.84±6.7345 P. Rukthong et al. / Songklanakarin J. Sci. Technol. 35 (1), 41-50, 2013
3.3.4  Limit of detection and quantitation
The lower limit of detection (LOD), estimated as the
amount of atorvastatin furnishing a signal three time greater
than the noise (S/N=3:1), was shown to be 0.05 ng/ml.  The
lower limit of quantitation (LLOQ) was defined as the lowest
concentration that can be measured with acceptable accuracy
and precision, and found to be 0.2 ng/ml in human plasma.
The mean response for analyte peak at the assay sensitivity
limit  (0.2  ng/ml)  was  about  5  fold  greater  than  the  mean
response for peak in six blank human plasma samples at the
retention time of the analyte. The between-batch precision
at the LLOQ was 3.475% and between-batch accuracy was
99.18% (Table 3).
3.3.5  Accuracy and precision
The within-batch for QC samples precision were 3.48-
9.28% and accuracy were 99.18-115% (Table 3). The results
showed that for within run and between run experiments the
precision and accuracy for the analyte were within the accep-
tance criteria (Table 3).
3.3.6  Stability
In case of stability, accuracy and precision of analysis
wer  in the acceptable range according to the US-FDA guide-
line implying that atorvastatin in plasma was stable under the
various condition: short-term 24 h, three freeze-thaw cycles,
auto sampler 24 h, and long-term for 3 months at -20°C (Table
4).
3.4 Pharmacokinetics of atorvastatin in healthy volunteers
Mean  values  of  pharmacokinetic  parameters  of
atorvastatin were obtained from the plasma-concentration
time  curve  for  each  subject  in  the  study.  The  atorvastatin
plasma concentration-time data from the study were analyzed
using WinNonlin
® professional edition version 3.1, using the
non-compartmental model. Four parameters were studied
C max,  AUC0-last,  AUC0-inf (observe)  and  Tmax  (Table 5).  These
parameters are commonly used in pharmacokinetics analysis.
The  plasma  concentrations  of  atorvastatin,  at  specified
sampling time, from 24 healthy Thai subject following oral
administration  of  40  mg  dose  were  presented  as  plasma-
concentration time. Spaghetti plots for plasma concentration
time profile of atorvastatin for all subjects are shown in Fig-
ure 8A, 8B. The mean and SD value of atorvastatin at speci-
fied sampling time obtained from 24 healthy Thai subjects
are presented in Table 5. For most subjects, atorvastatin was
rapidly absorbed. It reached a maximum concentration within
1-2 hour.  The largest maximum plasma concentration was 36
Figure 3.  Full scan positive ion TurboIonspray Q1 mass spectra of internal standard (fluvastatin).P. Rukthong et al. / Songklanakarin J. Sci. Technol. 35 (1), 41-50, 2013 46
Figure 4.  Full scan positive ion TurboIonspray product mass spectra of internal standard (Fluvastatin).
Table 3. Precision and accuracy of the method for determining atorvastatin concentrations in
Accuracy and QC samples Concentration added Concentration found CV Accuracy
     precision (ng/ml) (mean ± SD n = 6) (ng/ml) (%) (%)
  Intra-day LLOQ 0.2     0.099±0.003 3.47 99.18
Low 0.25     0.250±0.022 8.87 99.95
Mid 10     11.37±0.082 0.72 113.67
High 40     45.18±0.646 1.43 113
  Inter-day LLOQ 0.2 0.1068±0.006 6.226 106.8
Low 0.25 0.2408±0.062 5.579 96.32
Mid 10       8.169±0.1164 2.348 99.11
High 40 0.474±1.29 3.235 101.19
ng/ml.
Data of maximum plasma concentration (C max), area
under the plasma-concentration time curve from time zero to
last time (AUC 0-last), area under the plasma-concentration
time curve from time zero to the infinity time from observed
(AUC 0-inf (observed)) and time to reach maximum plasma concen-
tration (T max) of atorvastatin after single dose oral administra-
tion of 40 mg atorvastatin tablet of the atorvastatin product
were  compared  to  the  result  described  by  Koytchev  et  al.
(Koytchev et al., 2004)
The geometric mean values of area under the plasma-
concentration  time  curve  from  time  zero  to  the  last  time
(AUC0-inf)  for  atorvastatin,  between  33.5-149.3  ng*ml/h,
reflect  the  high  variability  of  the  pharmacokinetics  of
atorvastatin may occur from pharmacogenetic variations such
as Transporters, CYP450 etc. (Shitara and Sugiyama, 2006;
Kameyama et al., 2005; Thompson et al., 2005; Kajinami et al.,
2004). The mean values were approximately the same values
obtained by LC-MS/MS after administration of single dose
of atorvastatin (Kantola, Kivisto and Neuvonen, 1998; Borek-47 P. Rukthong et al. / Songklanakarin J. Sci. Technol. 35 (1), 41-50, 2013
Dohalsky et al., 2006) (Table 6). In contrast, results obtained
by HPLC UV methods were different (Nirogi, Mudigonda and
Kandikere, 2007). The comparative dose proportionality of
the pharmacokinetics of atorvastatin and the peak concentra-
tion (C max) of atorvastatin was in agreement with reported
data. The observed median values and range of atorvastatin
(T max) were 1.25 hours and 0.2-6 hours, respectively.  Com-
paring to the previous reported values, the median was not
different, while the range was wider. Because foods consider-
ably reduce the rate of atorvastatin absorption, the difference
Figure 5. MRM  ion-chromatograms  resulting  from  the  analysis  of  QC  sample  human  plasma  for  atorvastatin  (5A,  5B)  and  internal
standard (5C).
Figure 6. MRM ion-chromatograms resulting from the analysis of blank (drug and internal standard free) human plasma for atorvastatin
and internal standard.P. Rukthong et al. / Songklanakarin J. Sci. Technol. 35 (1), 41-50, 2013 48
may  also  be  because  of  the  longer  fasting  period  in  this
study, at least 8 hours rather than the 1 to 2 hours report by
Kantola et al. and Lilja et al., respectively. The median elimi-
nation half-life was 7.9 hours (range 1.2 to 21 hours) which
was consistent with several reports.
4. Conclusion
The  bioanalytical  methodology  described  in  this
report was specific, sensitive, accurate and precise enough to
be  successfully  applied  to  pharmacokinetics  study.  The
method employed sample preparation by solid phase micro-
extraction (SPME) appeared to be adequate recovery includ-
ing  less  time  consuming,  and  was  followed  by  gradient
HPLC  coupled  with  tandem  mass  spectrometric  detection
(LC-MS/MS).  The  LC-MS/MS  method  could  be  used  to
determination of atorvastatin in human plasma, in the con-
centration range 0.2-80 ng/ml. There were no interferences
from endogenous plasma component or other sources. The
need  for  plasma  volume  less  than  250  ml  for  each  sample
made it possible to decrease volume of sample preparation
per time. The method was successfully validated and proved
appropriate for the analysis of atorvastatin in human plasma
and can be applied for pharmacokinetics studies. The analy-
tical  method  presented  here  has  proved  to  be  useful  for
investigation of the characteristics of atorvastatin in human
plasma in pharmacokinetic and pharmacogenetic studies.
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